» Articles » PMID: 15147954

Invasiveness of Breast Carcinoma Cells and Transcript Profile: Eph Receptors and Ephrin Ligands As Molecular Markers of Potential Diagnostic and Prognostic Application

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2004 May 19
PMID 15147954
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

The Eph family of receptors, with 14 members in humans, makes up the largest group of receptor tyrosine kinases. These Eph receptors, along with their ligands, the 8 members of the ephrin family of ligands are involved in diverse developmental functions, including hindbrain development in vertebrates, tissue patterning, and angiogenesis. These Eph receptors and ephrin ligands have also been identified as important regulators in the development and progression of cancer. We have presented here a systematic and comprehensive investigation of the Eph/ephrin expression profiles of MCF-10A, MCF-7, and MDA-MB-231 cells representing normal breast, non-invasive breast tumor, and invasive tumor, respectively, based on their characteristic phenotypes in Matrigel matrix. The data have allowed us to correlate the gene expression profile with the cell phenotype that has potential application in tumor diagnostics. We demonstrate here that upregulation of EphA2, A7, A10, and ephrinA2 and B3 is likely involved in tumorigenesis and/or invasiveness, while downregulation of EphA1, A3, A4, A8, B3, B4, B6, and ephrinA1 and B1 may be particularly important in invasiveness. Based on these results we discuss the role of EphA2 and ephrinA1 combination in malignancy. The data have provided clues as to the importance of these molecules in the progression of breast cancer and specifically identified EphB6, a kinase-deficient receptor, which is downregulated in the most aggressive cell line, as reported for several other cancer types including neuroblastoma and melanoma suggesting its potential as a prognostic indicator in breast cancer as well.

Citing Articles

Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics.

Liu J, Yuan Q, Chen X, Yang Y, Xie T, Zhang Y Sci Rep. 2024; 14(1):17650.

PMID: 39085301 PMC: 11291735. DOI: 10.1038/s41598-024-68385-9.


Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.

Kashyap D, Salman H Int J Mol Sci. 2024; 25(7).

PMID: 38612592 PMC: 11011362. DOI: 10.3390/ijms25073780.


Co-Delivery of siRNA and Docetaxel to Cancer Cells by NLC for Therapy.

Senel B, Basaran E, Akyil E, Guven U, Buyukkoroglu G ACS Omega. 2024; 9(10):11671-11685.

PMID: 38496987 PMC: 10938417. DOI: 10.1021/acsomega.3c09098.


Association of clinicopathologic and molecular factors with the occurrence of positive margins in breast cancer.

Praveen Kumar A, Vicente D, Liu J, Raj-Kumar P, Deyarmin B, Lin X Breast Cancer Res Treat. 2023; 204(1):15-26.

PMID: 38038766 PMC: 10805852. DOI: 10.1007/s10549-023-07157-x.


An Overview of the Molecular Cues and Their Intracellular Signaling Shared by Cancer and the Nervous System: From Neurotransmitters to Synaptic Proteins, Anatomy of an All-Inclusive Cooperation.

Arese M, Bussolino F, Pergolizzi M, Bizzozero L Int J Mol Sci. 2022; 23(23).

PMID: 36499024 PMC: 9739679. DOI: 10.3390/ijms232314695.